GSK’s long-qui­et can­cer R&D group is ready to make some noise as it mounts a break­out late-stage ef­fort

SAN FRAN­CIS­CO — Four years af­ter GSK swapped out its com­mer­cial port­fo­lio of can­cer drugs to No­var­tis, new CEO Em­ma Walm­s­ley is now ready to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.